Ligand Pharmaceuticals Incorporated (LGND) Q4 2016 Earnings Results

Ligand Pharmaceuticals Misses on EPS — Stock Down 0.42%

Ligand Pharmaceuticals reported lower-than-expected earnings per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. The stock's modest drop reflects market caution following the earnings report.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.74	N/A	-27.45%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current market conditions impacting performance. They did not provide specific guidance for future quarters.

Management did not provide specific revenue guidance for the upcoming quarters.

The company acknowledged challenges in meeting earnings expectations.

Ligand Pharmaceuticals Misses on EPS — Stock Down 0.42%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Misses on EPS — Stock Down 0.42%

Key numbers

Management commentary